About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer

doi:10.1016/j.mce.2004.02.021

Molecular and Cellular Endocrinology

Volume 219, Issues 1–2, 30 April 2004, Pages 1-7

https://doi.org/10.1016/j.mce.2004.02.021 Get rights and content

Abstract

In breast tumours and breast cancer cell (BCC) lines, microarray analyses have revealed that a series of genes are expressed in close association with the oestrogen receptor-α (ER-α) gene, ESR1. Three of them, GATA3, HNF3A (also known as FOXA1), and XBP1 encode transcription factors. Here, we present these factors and we discuss their potential involvement in the ER-α-mediated actions in BCC. We notably show the relations that exist, or that might exist, between these factors and the oestrogen-inducible trefoil factor TFF1.

Introduction

The main mediator of anti-oestrogens action, the oestrogen receptor-α (ER-α, gene ESR1), plays a key role in the biology and treatment of breast cancer (Osborne et al., 2001, Leclercq et al., 2002). Global gene expression analyses have revealed that it is a major discriminator in breast cancer and breast cancer cell (BCC) lines classification. Numerous studies, notably based on microarray use, have shown that the expression of GATA3, HNF3A (also known as FOXA1), and XBP1 is strongly and positively correlated to that of ESR1 (Hoch et al., 1999, Perou et al., 2000, Bertucci et al., 2000, Sorlie et al., 2001, Sorlie et al., 2003, West et al., 2001, Gruvberger et al., 2001, Ross and Perou, 2001, van’t Veer et al., 2002, Sotiriou et al., 2003; reviewed in Lacroix and Leclercq, 2004). These genes encode transcription factors, the role of which in regulating BCC activities remains largely unknown. In an attempt to solve this question, we reviewed the literature concerning the biological function of these proteins. On the basis of these data, we suggest their possible involvement in the ER-α-mediated responses of BCC.

Section snippets

GATA-binding protein 3

GATA-3 is member of a family of six (GATA-1 to -6) transcription factors containing two zinc fingers. The C-terminal finger is capable of tight, specific binding to the (A/T)GATA(A/G) consensus DNA sequence. Differences in the N-terminal DNA binding domain are likely to provide a mechanism for more selective transcriptional control of target genes by the various GATA proteins (Takemoto et al., 2002). Whereas GATA-1, -2, and -3 expression has been predominantly observed in haematopoietic cells,

Differences and similarities in mechanisms underlying ESR1, GATA3, HNF3A, and XBP1 expression: a few words

Despite the close correlation existing between ESR1, GATA3, HNF3A, and XBP1 expression in breast cancer, none of the factors encoded by the three latter genes has been shown to date to play a role in ESR1 regulation. Interestingly, a microarray-mediated study has shown that GATA3, HNF3A, and XBP1 expression is not correlated to that of ESR1 in ovarian tumours. Indeed, these three genes appear more highly expressed in breast cancer than in ovarian carcinomas (Schaner et al., 2003). It is well

Potential involvement of GATA-3, HNF-3α, and XBP-1 in ER-α-mediated actions in BCC

Biological properties reported over here suggest that all three factors described can or could be actors in steroid receptor-mediated transcription of target genes. An involvement of GATA-3 and HNF-3α in the androgen regulation of prostate-specific genes has been documented, and data available strongly suggest that like XBP-1, they could modulate the ER-α-mediated gene regulation in BCC.

The induction of cell proliferation is a major effect mediated by ER-α in BCC. This process needs energy to

Acknowledgements

This work was supported by “Fonds Jean-Claude Heuson” and “Fonds Medic”. Marc Lacroix is supported by grants from Eppendorf Array Technologies (EAT, Namur, Belgium) and from European Communities (BreastMed Consortium, INCO MED ICA3-CT-2002-1005).

References (67)

E.D Al-Azzeh et al.
Transcription factor GATA-6 activates expression of gastroprotective trefoil genes TFF1 and TFF2
Biochim. Biophys. Acta
(2000)
G.G Gibson et al.
Receptor-dependent regulation of the CYP3A4 gene
Toxicology
(2002)
A Jacob et al.
The HNF-3alpha transcription factor is a primary target for retinoic acid action
Exp. Cell. Res.
(1999)
K.H Kaestner
The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism
Trends Endocrinol. Metab.
(2000)
J Kim et al.
Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells
J. Steroid Biochem. Mol. Biol.
(2000)
V.N Kristensen et al.
Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism
Mutat. Res.
(2000)
C.E McPherson et al.
An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array
Cell
(1993)
R Métivier et al.
Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter
Cell
(2003)
C.M Perez-Stable et al.
A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer
Mol. Cell. Endocrinol.
(2000)
R.J Playford et al.
Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration
Gastroenterology
(1995)

V Rider et al.

Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus

Int. Immunopharmacol.

(2001)

D Robyr et al.

Determinants of vitellogenin B1 promoter architecture. HNF3 and estrogen responsive transcription within chromatin

J. Biol. Chem.

(2000)

D.T Rutkowski et al.

A trip to the ER: coping with stress

Trends Cell. Biol.

(2004)

G.F Sewack et al.

Nucleosome positioning and transcription-associated chromatin alterations on the human estrogen-responsive pS2 promoter

J. Biol. Chem.

(1997)

Y Tomaru et al.

A comprehensive search for HNF-3alpha-regulated genes in mouse hepatoma cells by 60 K cDNA microarray and chromatin immunoprecipitation/PCR analysis

Biochem. Biophys. Res. Commun.

(2003)

C Tomasetto et al.

pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins

Gastroenterology

(2000)

H Yoshida et al.

XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor

Cell

(2001)

T Barkhem et al.

Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context

Mol. Endocrinol.

(2002)

S Beck et al.

Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box

DNA Cell. Biol.

(1999)

F Bertucci et al.

Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Hum. Mol. Genet.

(2000)

C Bossenmeyer-Pourié et al.

The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis

J. Cell. Biol.

(2002)

T Bouras et al.

Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer

Cancer Res.

(2002)

S Cereghini

Liver-enriched transcription factors and hepatocyte differentiation

FASEB J.

(1996)

C.H Chen et al.

Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression

J. Immunol.

(2000)

L.A Cirillo et al.

Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome

EMBO J.

(1998)

K.L Clark et al.

Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5

Nature

(1993)

R.H Costa et al.

Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes

Mol. Cell. Biol.

(1989)

H.E Cunliffe et al.

The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles

Cancer Res.

(2003)

A Dignass et al.

Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway

J. Clin. Invest.

(1994)

L Ding et al.

Ligand-independent activation of estrogen receptor alpha by XBP-1a

Nucleic Acids Res.

(2003)

Q.P Dou et al.

Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy

Prog. Cell. Cycle Res.

(2003)

G Flouriot et al.

Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage

Mol. Endocrinol.

(1998)

N Gao et al.

The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes

Mol. Endocrinol.

(2003)

Cited by (122)

Activation of kappa opioid receptor (KOR) inhibits estrogen receptor (ER)-positive breast cancer through the KOR-ER-XBP1 pathway
2023, Biomedicine and Pharmacotherapy
Opioids are commonly used in patients with breast cancer (BC), both for perioperative analgesia and for the relief of chronic cancer pain. Studies have suggested a potential association of opioid receptors (ORs) with the prognosis of BC patients. However, the exact roles of different ORs remain poorly understood. In this study, we found that κ opioid receptor (KOR) was the only OR (among the four types of ORs) that was significantly decreased in BC tumor tissues compared with peritumoral normal tissues. In addition, decreased expression of KOR correlated with poor clinical outcomes in patients with estrogen receptor (ER)-positive BC. In vitro studies confirmed the anti-tumor effects of KOR agonists in ER-positive MCF-7 and T47D cells by showing that activation of KOR significantly inhibited cellular proliferation and promoted apoptosis. Using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction network (PPI) analysis, we found that KOR-ER-XBP1 was the potential downstream signaling pathway mediating the anti-tumor effects of KOR agonist. Finally, the role of XBP1 was confirmed as KOR activation-induced increase in the proliferative and monoclonal formation abilities of ER-positive BC cells were both significantly abolished after silencing of XBP1. These findings provide us a better understanding of the roles of different ORs in BC, identifying KOR agonists as better opioids than traditional μ opioid receptor (MOR) agonists for providing analgesia in ER-positive BC patients owing to their association with better prognosis.
Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer
2021, Annals of Diagnostic Pathology
Citation Excerpt :
On the contrary, PTGS2 was significantly downregulated in both luminal A and luminal B subtypes as well as HER2 enriched subtype. PTGS2, also known as COX-2, is important for the synthesis of prostaglandins, which stimulate proliferation and metastasis of breast cancer cells [34]. High expression of PTGS2 is associated with poor prognosis and aggressive types of breast cancer with high histologic grade, negative ER, and triple negative breast cancer [38-40].
Breast cancer is a heterogeneous disease, and new biomarkers are needed for more accurate classification and prediction of prognosis. The goal of this study is to assess the expression of breast cancer classification genes, to identify new molecular signatures in different intrinsic subtypes of breast cancer and to correlate their expression with different clinical variables. The study included 84 female patients newly diagnosed with non-metastatic breast cancer at the outpatient clinic at the National Cancer Institute, Cairo University, Egypt. Detection of 17 breast cancer classification genes was done using RT-PCR in tumor and normal tissues. Estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 expression were assessed using IHC assay for intrinsic subtyping. Combined expression of FOXA1 and GATA3 was statistically higher in luminal subtypes in comparison to non-luminal subtypes. In Luminal A subtype; GRB7, EGFR, PTGS2, ID1, and KRT5 were significantly downregulated. FOXA1 and GATA3 were significantly upregulated in luminal B subtype, where EGFR and PTGS2 were significantly downregulated. While ESR1, EGFR, KRT5 and PTGS2 showed significantly low expression in tumor tissue in Her2 enriched subtype, TFF3 was significantly downregulated in triple negative subtype. GATA3 and FOXA1 expression exhibited significant correlation with tumor grade. Furthermore, GATA3, FOXA1, ESR1, and ID1 were also correlated significantly with staging of the tumor. Combined expression of ESR1, FOXA1 and GATA3 represents a molecular signature of luminal subtypes. Long term follow-up is needed to investigate the prognostic effect of breast cancer classification genes found in this study.
Indeno[1,2,3-cd]pyrene and picene mediate actions via estrogen receptor α signaling pathway in in vitro cell systems, altering gene expression
2020, Toxicology and Applied Pharmacology
Currently, the environmental impact of ubiquitous plastic debris triggered quite some public attention. However, the global impact of microplastic on human health is by and large either unknown or neglected. By looking at the underlying biochemical mechanisms leading to the global health threat microplastic was discovered to carry persistent organic pollutants, such as polycyclic aromatic hydrocarbons (PAH), to marine life. The effect of microplastic-ingestion in the human body remains unfortunately somewhat elusive as of yet. For this reason, we screened for compounds binding to the human estrogen receptor α (ERα) and identified the PAH compounds indeno[1,2,3-cd]pyrene (Indpy) and picene (Pice) with a high binding affinity. We applied next generation sequencing to analyze the differentially expressed genes in MCF-7 cells after treatment with Indpy and Pice. We found 8 upregulated genes: ABCC5, CCNG2, CYP1A1, DDIT4, IER3, RUNX2, STC2, and SLC7A5 and 14 downregulated genes: ADORA1, CEBPB, CELSR2, CTSD, CXCL12, KRT19, PGR, PKIB, RARA, RET, SEMA3B, SIAH2, TFAP2C, and XBP1 induced by both ligands and associated with ESR1-regulation. The altered gene expression may influence cell proliferation and metastasis, favoring cancer development with a poor response to therapy. In addition, we confirmed the binding of Indpy and Pice to ERα using molecular docking and microscale thermophoresis. ERα activation was measured with ESR1-overexpressing HEK293 (HEK-ESR1) cells and confirmed for Indpy. In conclusion, we showed an ESR1-mediated influence of the PAH compounds Indpy and Pice on the gene expression pattern of MCF-7 cells, possibly also promoting breast cancer development in patients.
Application of Single-Cell Omics in Breast Cancer
2019, Single-Cell Omics
The dynamics and heterogeneity of breast cancer undergoing clonal evolution produce cells with varying degrees of drug resistance and metastatic potential. Breast cancer is well known for different clinical behaviors and patient outcomes, in spite of common histopathological features at diagnosis. Currently, single-cell analysis has made remarkable advances, overshadowing the problem of heterogeneity linked with huge populations. Rapid progression in sequencing methods now permits unbiased, high-output, and high-resolution interpretation of heterogeneity from individual cells within a population. Conventional treatment strategies for individual patients are directed by the presence and absence of expression pattern of the estrogen and progesterone receptors (ER and PR) and human epidermal growth factor receptor 2 (HER2). Though such approaches for clinical classification have usefulness in selection of targeted therapies and short-term patient responses, they are unable to predict long-term survival. In any phenotypic alterations, like breast cancer disease, the molecular signature has proven its significance, as we know that an individual cell's state is controlled at diverse levels, such as DNA, RNA, and protein, by a multifaceted interplay of intrinsic biomolecule pathways existing in the organism and extrinsic stimuli such as the ambient environment. Thus for comprehensive understanding, complete profiling of a single-cell requires synchronous investigations from different levels (multiomics) to circumvent incomplete information produced from single-cells. In this chapter, initially we present current updates on the various methods available to explore omics and then we focus on omics (i.e., genomics, transcriptomics, epigenomics, proteomics, and metabolomics) data available from various studies that can be used for better management of breast cancer patients.
Pioneer Factors and Architectural Proteins Mediating Embryonic Expression Signatures in Cancer
2019, Trends in Molecular Medicine
Citation Excerpt :
Zhou and colleagues [22] identified that GATA4-GOF increased 4 times cell invasion and enhanced 1.5-fold migratory ability of nasopharyngeal cancer cells. GATA3 is required for mammary gland development and correlates with estrogen receptor alpha (ESR1) in breast cancer cells [23,24]. Moreover, loss of function (LOF) of GATA3 using a siRNA in breast cancer cells abolished the increased ESR1 expression induced by 3 h estradiol treatment.
Accumulation of mutations causing aberrant changes in the genome promotes cancer. However, mutations do not occur in every cancer subtype, suggesting additional events that trigger cancer. Chromatin rearrangements initiated by pioneer factors and architectural proteins are key events occurring before cancer-related genes are expressed. Both protein groups are also master regulators of important processes during embryogenesis. Several publications demonstrated that embryonic gene expression signatures are reactivated during cancer. This review article highlights current knowledge on pioneer factors and architectural proteins mediating chromatin rearrangements, which are the backbone of embryonic expression signatures promoting malignant transformation. Understanding chromatin rearrangements inducing embryonic expression signatures in adult cells might be the key to novel therapeutic approaches against cancers subtypes that arise without genomic mutations.
Application of single-cell omics in breast cancer
2019, Single-Cell Omics: Volume 2: Application in Biomedicine and Agriculture
The dynamics and heterogeneity of breast cancer undergoing clonal evolution produce cells with varying degrees of drug resistance and metastatic potential. Breast cancer is well known for different clinical behaviors and patient outcomes, in spite of common histopathological features at diagnosis. Currently, single-cell analysis has made remarkable advances, overshadowing the problem of heterogeneity linked with huge populations. Rapid progression in sequencing methods now permits unbiased, high-output, and high-resolution interpretation of heterogeneity from individual cells within a population. Conventional treatment strategies for individual patients are directed by the presence and absence of expression pattern of the estrogen and progesterone receptors (ER and PR) and human epidermal growth factor receptor 2 (HER2). Though such approaches for clinical classification have usefulness in selection of targeted therapies and short-term patient responses, they are unable to predict long-term survival. In any phenotypic alterations, like breast cancer disease, the molecular signature has proven its significance, as we know that an individual cell's state is controlled at diverse levels, such as DNA, RNA, and protein, by a multifaceted interplay of intrinsic biomolecule pathways existing in the organism and extrinsic stimuli such as the ambient environment. Thus for comprehensive understanding, complete profiling of a single-cell requires synchronous investigations from different levels (multiomics) to circumvent incomplete information produced from single-cells. In this chapter, initially we present current updates on the various methods available to explore omics and then we focus on omics (i.e., genomics, transcriptomics, epigenomics, proteomics, and metabolomics) data available from various studies that can be used for better management of breast cancer patients.

View all citing articles on Scopus

View full text

At the Cutting EdgeAbout GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer

Abstract

Introduction

Section snippets

GATA-binding protein 3

Differences and similarities in mechanisms underlying ESR1, GATA3, HNF3A, and XBP1 expression: a few words

Potential involvement of GATA-3, HNF-3α, and XBP-1 in ER-α-mediated actions in BCC

Acknowledgements

Biochim. Biophys. Acta

Toxicology

Exp. Cell. Res.

Trends Endocrinol. Metab.

J. Steroid Biochem. Mol. Biol.

Mutat. Res.

Cell

Cell

Mol. Cell. Endocrinol.

Gastroenterology

Int. Immunopharmacol.

J. Biol. Chem.

Trends Cell. Biol.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Gastroenterology

Cell

Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context

Mol. Endocrinol.

Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box

DNA Cell. Biol.

Gene expression profiling of primary breast carcinomas using arrays of candidate genes

Hum. Mol. Genet.

The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis

J. Cell. Biol.

Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer

Cancer Res.

Liver-enriched transcription factors and hepatocyte differentiation

FASEB J.

Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression

J. Immunol.

Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome

EMBO J.

Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5

Nature

Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes

Mol. Cell. Biol.

The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles

Cancer Res.

Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway

J. Clin. Invest.

Ligand-independent activation of estrogen receptor alpha by XBP-1a

Nucleic Acids Res.

Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy

Prog. Cell. Cycle Res.

Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage

Mol. Endocrinol.

The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes

Mol. Endocrinol.

At the Cutting Edge
About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer